Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients
US-2024382575-A1 · Nov 21, 2024 · US
Compositions and methods
US9795663B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9795663-B2 |
| Application number | US-201313930587-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 28, 2013 |
| Priority date | Jul 25, 2008 |
| Publication date | Oct 24, 2017 |
| Grant date | Oct 24, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for the treatment of latent tuberculosis comprising the administration of a polypeptide comprising: a polypeptide selected from the group consisting of SEQ ID Nos: 1 and 3-7 to a subject in need thereof, wherein said polypeptide induces an immune response. 2. The method according to claim 1 , wherein the subject has latent tuberculosis. 3. The method according to claim 1 , wherein the subject does not have tuberculosis.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9795663B2 cover?
- The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.
- Who is the assignee on this patent?
- Glaxosmithkline Biologicals Sa, Glaxosmithkline Biologicals Sa
- What technology area does this patent fall under?
- Primary CPC classification A61K39/04. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).